drugset / Trial / NCT04165850

Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS

NCT04165850

Phase 2 Completed 16 enrolled NeuroSense Therapeutics Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability and routine disease progression measures (ALSFRS-R and Vital Capacity).

Timeline

Start
2019-11-25
Primary completion
2021-01-19
Completion
2021-01-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified
Subject Ciprofloxacin Small molecule